Infinium pharmachem IPO subscription is opening up on 31st March 2023 till 5th April 2023. According to the prospectus, the IPO consists of a total of 1,875,000 shares aggregating up to ₹25.31 Cr. The Equity Shares have a face value of Rs 10 each.
Infinium pharmachem IPO – The Company Business Description
Incorporated on November 21st, 2003, Infinium pharmachem is engaged in manufacturing and supplying Iodine, Iodine Derivatives, and Active Pharmaceutical Ingredients (APIs).
The Company also offers Contract Research and Manufacturing Services (CRAMS) to provide customized and fully confidential solutions to its clients.
Infinium pharmachem products cater to various industries such as Pharmaceutical & Biotech, Specialty & Performance Chemicals, Agrochemicals, Human Health, Animal Health, Cosmetics, Sanitation, Electrical, Electronics, and much more.
The company offers the widest range of Iodine derivatives with more than 250+ intermediates and 15+ APIs.
The company operates in China through its subsidiaries Shanghai Tajilin Industrial Co. Ltd to deal with the API requirements in China. This is a joint venture (JV) with Shanghai Witofly Chemical Co. Ltd.
Infinium pharmachem Limited Founders and Leadership team
Mr. Sanjay Viththalbhai Patel, Mr. Pravin Bhadabhai Madhani, and Mr. Mitesh Lavjibhai Chikhaliya are the promoters of the company.
Infinium pharmachem Limited Revenue and Profit
Infinium pharmachem IPO has been generating strong revenue from operations over the years. The total revenue of the company has increased from Rs. 3884.19 lakhs in FY2020 to Rs 9911.93 lakhs in FY2022.
For the Period ended September 30, 2022, the company registered total revenue of Rs. 7927.59 lakhs which are quite significant in terms of annual revenue. The profit after tax reached Rs. 600 lakhs by September 30, 2022, from Rs. 86.78 lakhs in FY 2020.
Infinium pharmachem SME IPO Review : Financial Snapshot
| All amounts in INR Lakhs (Year ended March 31) | FY 2020 | FY 2021 | FY 2022 | Half Year By Sept, 2022 |
| Revenue Operation | 3884.19 | 7053.07 | 9911.93 | 7927.59 |
| Total Income | 3941.64 | 7115.37 | 10005.25 | 7985.39 |
| Profit for the period | 86.78 | 272.99 | 668.57 | 600.14 |
| Earnings Per equity Share-Diluted | 9.19 | 26.80 | 60.07 | 10.84 |
| Net Cash from Operating Activities | 303.13 | 728.70 | 1,179.57 | 194.88 |
| Total Borrowings | 566.17 | 579.47 | 1,385.01 | 1614.71 |
| Net Worth | 424.74 | 702.32 | 1310.22 | 1855.77 |
| Net Asset Value/Book Value per Equity share | 41.78 | 69.08 | 128.88 | 36.51 |
Objective Behind the Infinium pharmachem IPO
Infinium pharmachem is planning to utilize the net proceeds as below.
- Marketing and Branding Expenses (including Registration in Reach – Europe, and other marketing expenses)
- Repayment of some of the Existing Loans
- Expansion of Existing Unit
- To Meet Incremental Working Capital Requirements
- General Corporate Purpose
Infinium pharmachem IPO: Do you invest?
- Infinium Pharmachem is financially strong with positive net cash inflow from operation activities over the years mentioned in RHP.
- Earning per share has also been increasing over the years.
- The company is into Contract Research and Manufacturing Services and pharma API business, for which demand is high in India.
- The company also has a JV with a Chinese company in Shanghai that will help to cater the China API market.
- Government of India is promoting pharma API industry through PLI scheme, that will benefit this company.
- I would love to invest in the company for short to medium term.
- However, looking at the current scenario where, stock market is volatile, it is wise as a retail investor to avoid investing in IPOs till the market stabilize.
Infinium pharmachem IPO Details
| Infinium pharmachem IPO Details | Infinium pharmachem IPO Date, Price and other details |
| Infinium pharmachem IPO Date | Mar 31, 2023 to Apr 5, 2023 |
| IPO Price | ₹135 per share |
| IPO Allotment date | Apr 11, 2023 |
| Refunds Initiation date | Apr 12, 2023 |
| Credit of Shares to Demat Account | Apr 13, 2023 |
| IPO Listing Date | Apr 17, 2023 |
| Offer for Sale | Nil |
| Fresh Issue | 1,875,000 shares (aggregating up to ₹25.26 Cr) |
| IPO Issue Size (Fresh Issue) | 1,875,000 shares (aggregating up to ₹25.26 Cr) |
| Minimum bid (lot size) For retail investor | 1 lot of 1000 shares Investment of ₹135,000 |
| Maximum bid (lot size) For retail investor | 1 lot of 1000 shares Investment of ₹135,000 |
| Retail Shares Offered | Not less than 50% of the Net Offer |
| Minimum bid (lot size) HNI investor | 2 lot of 1000 shares (2000) Investment of ₹270,000 |
| NII (HNI) Shares Offered | |
| Face Value | INR 10 per share |
| Listing on | NSE SME |
| Promoters | Mr. Sanjay Viththalbhai Patel, Mr. Pravin Bhadabhai Madhani, and Mr. Mitesh Lavjibhai Chikhaliya are the Promoters |
Infinium pharmachem IPO: Lead Managers and Contact
| Contact Details | Infinium pharmachem IPO Lead Managers |
| Infinium Pharmachem Limited 38 G.I.D.C Sojitra, Taluka – Sojitra, Dist. – Anand – 387240 Phone: +91-2692-238849 Email: info@infiniumpharmachem.com Website: https://infiniumpharmachem.com/ | SWASTIKA INVESTMART LIMITED Email Id: merchantbanking@swastika.co.in Phoner: +91-22-26254568-69 / 0731-6644244 |
Infinium pharmachem SME IPO Allotment Status
Infinium pharmachem SME IPO Allotment status will be available on Bigshare Services Pvt Ltd. To know your allotment status, get ready with your PAN number and click on this link. You may also reach out to Phone: 011-40450193-197, Facsimile: 011-26812683 Email: ipo@skylinerta.com;
More Across from our Website
We endeavor to help you to understand different aspects of a company before you invest in the company’s IPO, India IPO Trends 2023, New Companies in the Indian share market 2023. To know more information about business overview of each company, here are some suggested readings on company insights for investment – 10 Best IPOs in 2022, Tata Play IPO, Upcoming IPOs, Upcoming SME IPOs.